Proparacaine

Generic Name: Proparacaine

Brand Names: Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₆N_₂O_₃

CAS Number: 499-67-2

Unique Ingredient Identifier: B4OB0JHI1X

Background: Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication: Used as a local (ophthalmic) anesthetic.

Associated Conditions: Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Associated Therapies: Local Anaesthesia therapy

Clinical Trials

Early Patient Access Treatment Use Protocol CA204-220

Conditions: Multiple Myeloma

First Posted Date: 2016-08-04

Last Posted Date: 2023-12-19

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT02856438

Locations: 🇯🇵
Local Institution, Osaka-shi, Osaka, Japan

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone
Procedure: autologous stem cell transplantation

First Posted Date: 2016-07-25

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 53

Registration Number: NCT02843074

Locations: 🇺🇸
HCA Midwest Health/Research Medical Center, Kansas City, Missouri, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

and more 2 locations

Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat

Phase 1

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Panobinostat
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-06-16

Last Posted Date: 2017-04-25

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Registration Number: NCT02802163

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Phase 2

Active, not recruiting

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Drug: Ixazomib
Drug: Lenalidomide

First Posted Date: 2016-05-09

Last Posted Date: 2023-05-06

Lead Sponsor: Emory University

Target Recruit Count: 72

Registration Number: NCT02765854

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Michigan/Rogel Cancer Center, Ann Arbor, Michigan, United States

and more 1 locations

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Lymphoma
Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Durvalumab
Drug: Lenalidomide
Drug: Ibrutinib
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2016-04-11

Last Posted Date: 2023-11-18

Lead Sponsor: Celgene

Target Recruit Count: 106

Registration Number: NCT02733042

Locations: 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸
Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
🇫🇷
Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France

and more 62 locations

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Tumor Cell Collection
Procedure: Autologous Stem Cell Transplant
Drug: Melphalan
Procedure: Leukapheresis
Biological: Myeloma vaccine
Drug: GM-CSF
Drug: Lenalidomide

First Posted Date: 2016-04-05

Last Posted Date: 2024-05-07

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 203

Registration Number: NCT02728102

Locations: 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
University of Wisconsin Hospital & Clinics, Madison, Wisconsin, United States

and more 12 locations

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Biological: Peptides
Drug: Poly-ICLC
Drug: Lenalidomide

First Posted Date: 2016-03-28

Last Posted Date: 2021-01-11

Lead Sponsor: Nina Bhardwaj

Target Recruit Count: 13

Registration Number: NCT02721043

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Bortezomib
Drug: Pomalidomide
Drug: Nivolumab

First Posted Date: 2016-03-25

Last Posted Date: 2024-07-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 67

Registration Number: NCT02719613

Locations: 🇺🇸
Local Institution - 0009, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0002, Boston, Massachusetts, United States
🇯🇵
Local Institution - 0048, Koto-ku, Tokyo, Japan

and more 38 locations

Treatment of IgG4-Related Disease With Revlimid and Rituximab

Phase 1

Completed

Conditions: IgG4-related Disease
Autoimmune Pancreatitis
Immunoglobulin G Subclass 4 Related Disease
IgG4-related Sclerosing Cholangitis
Retroperitoneal Fibrosis

Interventions: Drug: Rituximab
Drug: Lenalidomide

First Posted Date: 2016-03-10

Last Posted Date: 2019-07-08

Lead Sponsor: Mayo Clinic

Target Recruit Count: 6

Registration Number: NCT02705638

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Other: Pharmacological Study
Drug: R-(-)-Gossypol Acetic Acid

First Posted Date: 2016-03-03

Last Posted Date: 2023-12-28

Lead Sponsor: Mayo Clinic

Target Recruit Count: 10

Registration Number: NCT02697344

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy